Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

OBJECTIVES. The aim of our study was to determine a superior thrombolytic regimen from three: anistreplase (APSAC), front-loaded recombinant tissue-type plasminogen activator (rt-PA) or combination thrombolytic therapy. BACKGROUND. Although thrombolytic therapy has been shown to reduce mortality and morbidity after acute myocardial infarction, it has not been clear whether more aggressive thrombolytic-antithrombotic regimens could improve the outcome achieved with standard regimens. METHODS. To address this issue, 382 patients with acute myocardial infarction were randomized to receive in a double-blind fashion (along with intravenous heparin and aspirin) APSAC, front-loaded rt-PA or a combination of both agents. The primary end point "unsatisfactory outcome" was a composite clinical end point assessed through hospital discharge. RESULTS. Patency of the infarct-related artery (Thrombolysis in Myocardial Infarction [TIMI] grade 2 or 3 flow) at 60 min after the start of thrombolysis was significantly higher in rt-PA-treated patients (77.8% vs. 59.5% for APSAC-treated patients and 59.3% for combination-treated patients [rt-PA vs. APSAC, p = 0.02; rt-PA vs. combination, p = 0.03]). At 90 min, the incidence of both infarct-related artery patency and TIMI grade 3 flow was significantly higher in rt-PA-treated patients (60.2% had TIMI grade 3 flow vs. 42.9% and 44.8% of APSAC- and combination-treated patients, respectively [rt-PA vs. APSAC, p < 0.01; rt-PA vs. combination, p = 0.02]). The incidence of unsatisfactory outcome was 41.3% for rt-PA compared with 49% for APSAC and 53.6% for the combination (rt-PA vs. APSAC, p = 0.19; rt-PA vs. combination, p = 0.06). The mortality rate at 6 weeks was lowest in the rt-PA-treated patients (2.2% vs. 8.8% for APSAC and 7.2% for combination thrombolytic therapy [rt-PA vs. APSAC, p = 0.02; rt-PA vs. combination, p = 0.06]). CONCLUSIONS. Front-loaded rt-PA achieved significantly higher rates of early reperfusion and was associated with trends toward better overall clinical benefit and survival than those achieved with a standard thrombolytic agent or combination thrombolytic therapy. These findings support the concept that more rapid reperfusion of the infarct-related artery is associated with improved clinical outcome.

This article has been cited by other articles:

				S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]

				D Gray Thrombolysis: past, present, and future. Postgrad. Med. J., June 1, 2006; 82(968): 372 - 375. [Abstract] [Full Text] [PDF]

				M. S. Sabatine, D. A. Morrow, R. P. Giugliano, P. B.J. Burton, S. A. Murphy, C. H. McCabe, C. M. Gibson, and E. Braunwald Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes Circulation, April 26, 2005; 111(16): 2042 - 2049. [Abstract] [Full Text] [PDF]

				A. Schomig, G. Ndrepepa, J. Mehilli, J. Dirschinger, S. G. Nekolla, C. Schmitt, S. Martinoff, M. Seyfarth, M. Schwaiger, A. Kastrati, et al. A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2073 - 2079. [Abstract] [Full Text] [PDF]

				C. M. Gibson, S. A. Murphy, A. J. Kirtane, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, and TIMI Study Group Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with st-segment elevation myocardial infarction J. Am. Coll. Cardiol., September 1, 2004; 44(5): 980 - 987. [Abstract] [Full Text] [PDF]

				V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 549S - 575S. [Abstract] [Full Text] [PDF]

				C. M. Gibson, J. Karha, S. A. Murphy, D. James, D. A. Morrow, C. P. Cannon, R. P. Giugliano, E. M. Antman, E. Braunwald, and TIMI Study Group Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials J. Am. Coll. Cardiol., July 2, 2003; 42(1): 7 - 16. [Abstract] [Full Text] [PDF]

				O. Topaz, E. C. Perin, R. L. Jesse, P. K. Mohanty, M. Carr, and U. Rosenschein Power Thrombectomy in Acute Ischemic Coronary Syndromes Angiology, July 1, 2003; 54(4): 457 - 468. [Abstract] [PDF]

				K P Balachandran, J Miller, A C H Pell, B D Vallance, and K G Oldroyd Rescue percutaneous coronary intervention for failed thrombolysis: results from a district general hospital Postgrad. Med. J., June 1, 2002; 78(920): 330 - 334. [Abstract] [Full Text] [PDF]

				R. D. Welch, R. J. Zalenski, P. D. Frederick, J. A. Malmgren, S. Compton, M. Grzybowski, S. Thomas, T. Kowalenko, N. R. Every, and for the National Registry of Myocardial Infarction Prognostic Value of a Normal or Nonspecific Initial Electrocardiogram in Acute Myocardial Infarction JAMA, October 24, 2001; 286(16): 1977 - 1984. [Abstract] [Full Text] [PDF]

				S.G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A.J. Camm, R. Cappato, S.M. Cobbe, C. Di Mario, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology Eur. Heart J., August 2, 2001; 22(16): 1374 - 1450. [PDF]

				J. Llevadot, R. P. Giugliano, and E. M. Antman Bolus Fibrinolytic Therapy in Acute Myocardial Infarction JAMA, July 25, 2001; 286(4): 442 - 449. [Abstract] [Full Text] [PDF]

				C. M. Gibson, J. A. de Lemos, S. A. Murphy, S. J. Marble, C. H. McCabe, C. P. Cannon, E. M. Antman, and E. Braunwald Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction : A TIMI 14 Substudy Circulation, May 29, 2001; 103(21): 2550 - 2554. [Abstract] [Full Text] [PDF]

				A.M. Antman, J.A. de Lemos, and E. Braunwald Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction Eur. Heart J. Suppl., May 1, 2001; 3(suppl_A): A8 - A13. [Abstract] [PDF]

				E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy Intravenous Thrombolysis in Acute Myocardial Infarction Chest, January 1, 2001; 119 (2009): 253S - 277S. [Full Text] [PDF]

				C. P. Cannon, C. M. Gibson, C. T. Lambrew, D. A. Shoultz, D. Levy, W. J. French, J. M. Gore, W. D. Weaver, W. J. Rogers, and A. J. Tiefenbrunn Relationship of Symptom-Onset-to-Balloon Time and Door-to-Balloon Time With Mortality in Patients Undergoing Angioplasty for Acute Myocardial Infarction JAMA, June 14, 2000; 283(22): 2941 - 2947. [Abstract] [Full Text] [PDF]

				N. M Robinson and A. D Timmis Reperfusion in acute myocardial infarction BMJ, May 20, 2000; 320(7246): 1354 - 1355. [Full Text]

				R. Yuval, D. A. Halon, A. Merdler, N. Khader, B. Karkabi, K. Uziel, and B. S. Lewis Patient Comprehension and Reaction to Participating in a Double-blind Randomized Clinical Trial (ISIS-4) in Acute Myocardial Infarction Arch Intern Med, April 24, 2000; 160(8): 1142 - 1146. [Abstract] [Full Text] [PDF]

				A. Chiu, W.-K. Chan, S.-H. Cheng, C.-K. Leung, and C.-H. Choi Troponin-I, myoglobin, and mass concentration of creatine kinase-MB in acute myocardial infarction QJM, December 1, 1999; 92(12): 711 - 718. [Abstract] [Full Text] [PDF]

				C. P. Cannon Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1395 - 1402. [Abstract] [Full Text] [PDF]

				C. M. Gibson, S. Murphy, I. B. A. Menown, R. F. Sequeira, R. Greene, F. Van de Werf, M. J. Schweiger, M. Ghali, M. J. Frey, K. A. Ryan, et al. Determinants of coronary blood flow after thrombolytic administration J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1403 - 1412. [Abstract] [Full Text] [PDF]

				C. M. Gibson, K. A. Ryan, S. A. Murphy, R. Mesley, S. J. Marble, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, and for the TIMI Study Group Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction J. Am. Coll. Cardiol., October 1, 1999; 34(4): 974 - 982. [Abstract] [Full Text] [PDF]

				M. J. Tanasijevic, C. P. Cannon, E. M. Antman, D. R. Wybenga, G. A. Fischer, C. Grudzien, C. M. Gibson, J. W. Winkelman, E. Braunwald, and for the TIMI 10B Investigators Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: Results from the thrombolysis in myocardial infarction study (TIMI) 10B J. Am. Coll. Cardiol., September 1, 1999; 34(3): 739 - 747. [Abstract] [Full Text] [PDF]

				I.-K. Jang, D. F. M. Brown, R. P. Giugliano, H. V. Anderson, D. Losordo, J. C. Nicolau, O. P. Dutra, O. Bazzino, V. M. Viamonte, R. Norbady, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) study J. Am. Coll. Cardiol., June 1, 1999; 33(7): 1879 - 1885. [Abstract] [Full Text] [PDF]

				E. M. Antman, R. P. Giugliano, C. M. Gibson, C. H. McCabe, P. Coussement, N. S. Kleiman, A. Vahanian, A. A. J. Adgey, I. Menown, H.-J. Rupprecht, et al. Abciximab Facilitates the Rate and Extent of Thrombolysis : Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial Circulation, June 1, 1999; 99(21): 2720 - 2732. [Abstract] [Full Text] [PDF]

				C. M. Gibson, S. A. Murphy, M. J. Rizzo, K. A. Ryan, S. J. Marble, C. H. McCabe, C. P. Cannon, F. Van de Werf, and E. Braunwald Relationship Between TIMI Frame Count and Clinical Outcomes After Thrombolytic Administration Circulation, April 20, 1999; 99(15): 1945 - 1950. [Abstract] [Full Text] [PDF]

				C. P. Cannon, C. H. McCabe, C. M. Gibson, M. Ghali, R. F. Sequeira, G. R. McKendall, J. Breed, N. B. Modi, N. L. Fox, R. P. Tracy, et al. TNK-Tissue Plasminogen Activator in Acute Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A Dose-Ranging Trial Circulation, January 21, 1997; 95(2): 351 - 356. [Abstract] [Full Text]

				C. Bode, R. W. Smalling, G. Berg, C. Burnett, G. Lorch, J. M. Kalbfleisch, R. Chernoff, L. G. Christie, R. L. Feldman, A. A. Seals, et al. Randomized Comparison of Coronary Thrombolysis Achieved With Double-Bolus Reteplase (Recombinant Plasminogen Activator) and Front-Loaded, Accelerated Alteplase (Recombinant Tissue Plasminogen Activator) in Patients With Acute Myocardial Infarction Circulation, September 1, 1996; 94(5): 891 - 898. [Abstract] [Full Text]

				E. M. Antman Hirudin in Acute Myocardial Infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial Circulation, September 1, 1996; 94(5): 911 - 921. [Abstract] [Full Text]

				C. M. Gibson, C. P. Cannon, W. L. Daley, J. T. Dodge Jr, B. Alexander, S. J. Marble, C. H. McCabe, L. Raymond, T. Fortin, W. K. Poole, et al. TIMI Frame Count : A Quantitative Method of Assessing Coronary Artery Flow Circulation, March 1, 1996; 93(5): 879 - 888. [Abstract] [Full Text]

				Benefits of Front-Loaded rt-PA in Acute MI (TIMI 4 Trial) Journal Watch Cardiology, February 1, 1995; 1995(201): 16 - 16. [Full Text]

				R. A. Kloner, T. Shook, K. Przyklenk, V. G. Davis, L. Junio, R. V. Matthews, S. Burstein, C. M. Gibson, W. K. Poole, C. P. Cannon, et al. Previous Angina Alters In-Hospital Outcome in TIMI 4 : A Clinical Correlate to Preconditioning? Circulation, January 1, 1995; 91(1): 37 - 45. [Abstract] [Full Text]

				K. M. Choi, R. J. Kim, G. Gubernikoff, J. D. Vargas, M. Parker, and R. M. Judd Transmural Extent of Acute Myocardial Infarction Predicts Long-Term Improvement in Contractile Function Circulation, September 4, 2001; 104(10): 1101 - 1107. [Abstract] [Full Text] [PDF]